| 名稱 | SIRPɑ/PD-1 Dual Effector Reporter Cell |
| 型號 | CBP74154 |
| 報價 |  |
| 特點 | SIRPɑ/PD-1 Dual Effector Reporter Cell |
產(chǎn)品搜索
相關(guān)文章
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
- 詳細內(nèi)容
| CBP74154 | |
| I. Background | |
SIRP alpha protein, or Signal regulatory proteinalpha (SIRP-α), also known as Tyrosine protein phosphatase non-receptor type substrate 1, CD172a, Bit, and MyD-1, GenBank Accession No. NM_080792, a.a. 27-370, with C-terminal Avi and His tags, MW 40.3 kDa*. This SIRP alpha protein acts as a receptor for CD47; a.a. 27-370 correspond to the extracellular portion of SIRP-α. *Note: SIRP-α is heavily glycosylated, resulting in higher molecular weight. The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and enables cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes | |
| II. Introduction | |
| Expressed gene: | SIRPɑ、PD-1 |
| Stability: | 32 passages(in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | SIRPɑ、PD-1 |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+2ug/ml puromycin+ 5ug/ml blasticidin+200ug/ml hygromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Representative Data | |
Figure 1. Dose response of Blocking Antibodies in SIRPα/PD-1 Dual Effector Reporter Cells(C18) With CD47/PD-L1 Dual Target Cells. | |
